NCT01829568 - Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2013

Primary Completion Date

May 11, 2015

Study Completion Date

June 6, 2026

Conditions

Ann Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 3 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 3 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Rituximab

Given IV

Trial Locations (7)

10065

NYP/Weill Cornell Medical Center, New York

14263

Roswell Park Cancer Institute, Buffalo

20007

MedStar Georgetown University Hospital, Washington D.C.

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

43210

Ohio State University Comprehensive Cancer Center, Columbus

60637

University of Chicago Comprehensive Cancer Center, Chicago

02215

Dana-Farber Cancer Institute, Boston